Compare Novo Nordisk A/S (NVO) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Simon Property Group Inc — how do they compare? Novo Nordisk A/S trades at $44.91 (market cap $200.69B), while Simon Property Group Inc trades at $206.11 (market cap $68.56B). The key difference: Novo Nordisk A/S is far larger — about 2.9× Simon Property Group Inc's market cap, and Simon Property Group Inc pays the higher dividend (4.2%). Which is the better fit depends on your goals.
| NVO | SPG | |
|---|---|---|
Market Cap | $200.69B | $68.56B |
Sector | Health | Real Estate |
52-Week High | $63.98 | $236.70 |
52-Week Low | $35.29 | $173.35 |
Enterprise Value | $215.49B | $97.00B |
Dividend Yield | 3.98% | 4.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
SPG trades at $211.88, up 1.17% daily, with a bearish technical signal but strong fundamentals including a P/E of 14.95, robust net income margin of 66.57%, and recent Q2 2026 FFO beat. The company raised $800 million in senior notes (PRNewsWire, 2026-09-09) and launched Simon Media Network to monetize mall traffic (PRNewsWire, 2026-08-27), enhancing growth prospects despite a Q2 EPS miss.
Outlook is mixed: analyst consensus targets $231.82 with 42% buy ratings, but risks include high debt ($24.21B long-term) and bearish technicals. Opportunities lie in dividend yields and media initiatives, while headwinds involve retail real estate volatility and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
